Bispecific Antibodies Market - Strategic Insights and Forecasts (2026-2031)

The bispecific antibodies market is expected to register strong growth during the forecast period from 2026 to 2031, driven primarily by oncology applications and expanding biologic innovation.

T-cell engaging bispecific antibodies redirect cytotoxic T-cells toward cancer cells, helping the immune system attack malignant cells more effectively without extensive immune priming.

Oncology remains the dominant therapeutic area, particularly multiple myeloma, lymphoma, lung cancer, and gastric cancer. Ophthalmology applications are also emerging rapidly.

Major drivers include rising relapsed hematologic cancer populations, increasing demand for dual-target immune modulation, regulatory fast-track approvals, and advancements in antibody engineering technologies.

Key challenges include cytokine release syndrome risk, high manufacturing complexity, elevated production costs, and limited effectiveness in some solid tumors due to immunosuppressive tumor environments.